### **Overview** Aarti Drugs Limited (ADL), established in 1984, is a leading Indian manufacturer of **Active Pharmaceutical Ingredients (APIs)**, **pharmaceutical intermediates**, **specialty chemicals**, and **formulations**. Part of the **$6 billion Aarti Group of Industries**, the company operates with a vertically integrated, R&D-driven model across 14 manufacturing facilities—10 in Maharashtra, 3 in Gujarat, and 1 in Himachal Pradesh. ADL is recognized globally for its **cost leadership**, **high regulatory compliance**, and **backed by one of the largest R&D infrastructures in the domestic API sector**. --- ### **Core Strengths & Strategic Advantages** - **Vertically Integrated Operations**: Over **four decades of experience** in pharmaceutical manufacturing enables backward integration, reducing dependence on external raw material suppliers and enhancing supply chain resilience. - **Regulatory Excellence**: Facilities are approved by **USFDA, EU-GMP, UKMHRA, WHO-GMP, ANVISA, and COFEPRIS**, facilitating access to high-margin regulated markets. - **R&D-Driven Innovation**: Twin R&D centers at **Tarapur (API process development)** and **Turbhe (complex generics/formulations)** are **DSIR-accredited**, supporting kilo-scale pilot production and rapid commercialization. - **Cost & Scale Advantages**: Economies of scale, strong purchasing power, and end-to-end control drive **cost leadership** and **margin stability**, particularly in highly competitive markets like APIs. - **Diversified Global Footprint**: Products exported to **over 100 countries**; key markets include **Latin America, Asia, the Middle East, Africa, Europe, and North America**. --- ### **Business Segments & Key Products** #### **1. APIs (90% of Revenue)** - **Therapeutic Segments**: Antibiotics (37% of FY25 revenue), Antiprotozoals, Anti-inflammatories, Anti-diabetics, Antifungals, Cardiovascular. - **Leadership Position**: - World’s largest producer of **Metronidazole, Nimesulide, Ketoconazole, Tinidazole, and Fluoroquinolones**. - Among the **top global producers of Metformin**, with over **1,450 metric tons per month (TPM)** capacity. - Plans for **350 TPM brownfield expansion** in Metformin to meet rising demand. - **Installed API Capacity**: 45,511 MTPA across 9 units. #### **2. Specialty Chemicals & Intermediates** - Focus on **benzene and chloro-sulphonic chemistries**. - Key products: **Benzene Sulphonyl Chloride**, **Methyl Nicotinate**, and derivatives used across antibiotic, antifungal, anti-inflammatory, and cardiovascular APIs. - **13,742 MTPA installed capacity**; incremental expansions underway, with a greenfield project planned to grow this high-margin segment. #### **3. Formulations (13–15% of Revenue)** - Operated through fully owned subsidiary **Pinnacle Life Science Private Limited** (Baddi, Himachal Pradesh). - **WHO-GMP and USFDA-approved** facilities with annual capacities of **3 billion tablets and 300 million capsules**. - **Oncology formulations USFDA approved**; OSD plant UKMHRA-certified. - Strategic focus on **Latin America and Africa**, supported by **330 product registrations across 16 geographies** and subsidiaries: - **Pinnacle Chile SpA** - **Pharma Go SpA** - **Toll manufacturing** and **multi-purpose facilities** support flexibility and global expansion. --- ### **Recent Developments (2024–2025)** #### **Backward Integration & Capacity Expansion** - **Sayakha (Gujarat) Greenfield Project**: - **Anti-diabetic intermediates and APIs**; trialing since May 2025. - Designed for **100% captive consumption**; currently meeting **40–50%** of Metformin’s methyl amine requirements. - Expected to achieve **full integration within 6–12 months**, securing supply and boosting margins. - **Tarapur Salicylic Acid Plant**: - Commissioned in 2025; currently producing **300 tonnes/month**, targeting **500 tonnes/month by Q4 FY26** and **1,600 tonnes/month by FY26-end**. - Downstream **400 T/month salicylates line** in development to improve cost absorption and margin stability. - Plant expected to become **EBITDA positive** at 800 T/month. - **Methylamines (MMA, DMA, TMA)**: - DMA used internally in anti-diabetic APIs; **MMA and TMA sold externally**, diversifying revenue. - Facility operational since **Sept 2025**, reducing import dependency. #### **New Product Launches & Market Expansion** - **Bicalutamide**: To be commercialized in the **US market in Q3 FY26**, projected to add **₹60–70 crores in annual revenue**. - **Gliptins Launch**: Expanding presence in the **anti-diabetic API portfolio**, with launches expected in **Europe, UK, and non-US regulated markets**. - **Anti-inflammatory Multipurpose Facility**: Under construction; projected to generate **₹35–50 crores/year**. - **Dermatology Entry**: - Commissioned a **40,000 sq ft plant in Tarapur (Jan 2024)**. - Plans to launch **dermatology formulations** in psoriasis, acne, eczema. - Exploring **skincare and cosmetic applications** from PHBA, octyl salicylate, and other salicylic derivatives. #### **Strategic Growth & Margins** - **Capex Outlook**: - **Near-complete ₹600 crore capex program** focused on backward integration and capacity expansion. - **₹200 crore planned for FY26**, half already spent in H1. - **Future FY27 capex: ₹150–200 crores**, primarily for Metformin expansion. - **Margin Strategy**: - Current consolidated **EBITDA margin >13%**, targeting **15% (pre-COVID levels)** by FY26-27 via cost improvements, capacity utilization, and export mix shift. - Stabilization in **global API pricing** expected in **2H FY26**, particularly in anti-inflammatories and antibiotics. - **Revenue Outlook**: - Targeting **double-digit revenue growth in FY26**, driven by ramp-up in Sayakha/Tarapur, new product launches, and export recovery. - Future growth trajectory poised to scale from **₹5,000 crores to ₹10,000 crores**, contingent on next-gen product portfolio development (5–10 year roadmap). --- ### **Global Regulatory & Export Strategy** - Focus on **high-value, regulated markets (US, EU, Canada, Australia, Brazil)**. - **USFDA lifted import alert** on Tarapur API facility—critical for US market recovery. - **EU and USFDA certifications** underway for key products to **leverage lower-cost Indian manufacturing for export**. - Regulatory opportunities from **US China tariff policies**, enabling ADL to capture share in supply chain realignment. --- ### **R&D & Innovation Focus** - **Process Optimization**: - Developed **eco-friendly Metformin HCl process** reducing waste and impurities. - **Continuous flow reactor for Ciprofloxacin HCl** expected to improve yield and efficiency. - **New Molecule Pipeline**: - 15 **oncology products** in development. - Expanding into **DPP-4 inhibitors (Teneligliptin, Vildagliptin)** and **SGLT2 inhibitors**. - **Future R&D Expansion**: - Complex **semi-solids (creams, ointments)** and **oral liquids**. - **Thiophene derivatives** and **next-generation formulations** for Day 1 launches in regulated markets. --- ### **Operational & Environmental Initiatives** - **Sustainability & Energy Transition**: - **Group captive solar project** in development. - **Agro-based multi-fuel boiler** reducing fossil fuel dependence. - **Zero Liquid Discharge (ZLD)** model across all facilities. - **Advanced Process Technologies**: - ARDC (waste recovery), **reverse osmosis** for concentration, **automatic vertical press filters**, and **Freon-based chilling plants** improve efficiency and reduce environmental impact. --- ### **Risk & Mitigation** - **Pricing Pressure**: API prices faced declines (7–8% YoY in antibiotics), but stabilization seen in H2 FY26. - **Chinese Competition**: Proactively countering with **antidumping duty (ADD) filings** for salicylic acid and **import-substitute API development**. - **Export Volatility**: Destocking and dollar shortages in FY24 now easing; recovery seen in Latin America, Africa. --- ### **Financial & Capital Management** - **Funding Strategy**: Growth primarily funded via **internal accruals**; capex **phased to maintain low debt**. - **Customer Base**: Highly diversified—**top 10 clients <25% of sales**; no single client exceeds 5–6%. - **Revenue Mix (FY25)**: - **Exports: 63%**, Domestics: 37% - **Asia**: 52%, North America: 11%, Europe: 12% ---